CureVac NV Ordinary Shares CVAC
News
CureVac Partner GSK Announces Positive Phase 2 Data from Seasonal Influenza mRNA Vaccine Program
CureVac to Present First CVGBM Glioblastoma Cancer Vaccine Clinical Data at ESMO 2024 Congress
CureVac Announces Financial Results for the Second Quarter and First Half of 2024 and Provides Business Update
CureVac Advances Cancer Vaccine Candidate CVGBM to Part B of Phase 1 Study in Patients with Resected Glioblastoma
CureVac Names Oncologist and Drug Development Expert Dr. Mehdi Shahidi to Supervisory Board
CureVac Provides Update on Trial Dates for Patent Litigation Across Multiple Geographies Against Pfizer/BioNTech
CureVac's stock soars on GSK's $1.56 billion deal for its COVID-19 and flu vaccines
GSK to Buy CureVac's Covid-19, Flu Vaccine Rights for Up to $1.56 Billion — 2nd Update
GSK to Buy CureVac's Covid-19, Flu Vaccine Rights in Up to $1.56 Billion Deal — Update
GSK, CureVac Expand Licensing Agreement
Moderna, CureVac, other vaccine stocks jump as new human bird-flu cases reported in U.S., Australia
CureVac stock gains as COVID vaccine candidates show promise
CureVac Shares Hit All-Time Low on German Patent Court Ruling
CureVac signals progress on mRNA flu vaccine
United States